BMT CTN 1703/1801: A Randomized, Multi-Center, Phase III Trial of Tacrolimus/ Methotrexate versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (PROGRESS III)/Companion Study: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (Mi-Immune)
The primary objective of the trial is to compare 1 year GVHD-free, relapse-free survival (GRFS) between the two GVHD prophylaxis regimens.
- IRB Number: 1903006145 (BMTCTN1703/1801)
- Research Study Identifier: TX10537
- Principal Investigator: Sherif Farag, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required